ADAM8 as a drug target in pancreatic cancer
ADAM8 as a drug target in pancreatic cancer
About this item
Full title
Author / Creator
Schlomann, Uwe , Koller, Garrit , Conrad, Catharina , Ferdous, Taheera , Golfi, Panagiota , Garcia, Adolfo Molejon , Höfling, Sabrina , Parsons, Maddy , Costa, Patricia , Soper, Robin , Bossard, Maud , Hagemann, Thorsten , Roshani, Rozita , Sewald, Norbert , Ketchem, Randal R. , Moss, Marcia L. , Rasmussen, Fred H. , Miller, Miles A. , Lauffenburger, Douglas A. , Tuveson, David A. , Nimsky, Christopher and Bartsch, Jörg W.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with <5% survivors after 5 years. High expression levels of ADAM8, a metalloprotease disintegrin, are correlated with poor clinical outcome. We show that ADAM8 expression is associated with increased migration and invasiveness of PDAC cells caused by activation of ERK1/2 and higher MMP ac...
Alternative Titles
Full title
ADAM8 as a drug target in pancreatic cancer
Authors, Artists and Contributors
Author / Creator
Koller, Garrit
Conrad, Catharina
Ferdous, Taheera
Golfi, Panagiota
Garcia, Adolfo Molejon
Höfling, Sabrina
Parsons, Maddy
Costa, Patricia
Soper, Robin
Bossard, Maud
Hagemann, Thorsten
Roshani, Rozita
Sewald, Norbert
Ketchem, Randal R.
Moss, Marcia L.
Rasmussen, Fred H.
Miller, Miles A.
Lauffenburger, Douglas A.
Tuveson, David A.
Nimsky, Christopher
Bartsch, Jörg W.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5014123
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5014123
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/ncomms7175
